Paredes J, Krown S E
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Int J Immunopharmacol. 1991;13 Suppl 1:77-81. doi: 10.1016/0192-0561(91)90128-t.
High dose IFN-alpha is an effective treatment for a subset of patients with Kaposi's Sarcoma, that is, those who lack systemic symptoms (e.g. fever, weight loss), and co-existing HIV-associated conditions (e.g. opportunistic infections), and whose cell-mediated immunity system is only mildly or moderately impaired. There is little evidence that the addition of chemotherapeutic agents to IFN-alpha improves treatment outcome. Response rates in excess of 40% have been reported with the addition of AZT to IFN-alpha, and may prove active in patients with more severely impaired T-cell immunity. There is evidence that in responding patients, IFN-alpha also suppresses HIV replication, and in vitro studies indicate synergistic suppression of HIV by the IFN-alpha-AZT combination; evidence for in vitro synergy is being sought.
高剂量干扰素α是治疗卡波西肉瘤部分患者的有效方法，即那些没有全身症状（如发热、体重减轻）、不存在与HIV相关的并存病症（如机会性感染）且细胞介导免疫系统仅轻度或中度受损的患者。几乎没有证据表明在干扰素α治疗中添加化疗药物能改善治疗效果。据报道，在干扰素α治疗中添加齐多夫定（AZT）的缓解率超过40%，且可能对T细胞免疫受损更严重的患者有效。有证据表明，在有反应的患者中，干扰素α还能抑制HIV复制，体外研究表明干扰素α与AZT联合使用对HIV有协同抑制作用；正在寻找体外协同作用的证据。
